Epigenomics Collaborates with Myriad Genetics to Discover DNA Methylation Biomarkers
News May 15, 2007
Epigenomics AG has entered into R&D collaboration with Myriad Genetics, Inc. to identify and analyze DNA methylation biomarkers that may predict patients’ response to an undisclosed marketed oncology drug.
Under the agreement, Epigenomics will use its proprietary Differential Methylation Hybridization (DMH) microarray platform to perform genome-wide DNA methylation profiling on samples provided by Myriad and compare these profiles to identify DNA methylation biomarkers associated with sensitivity and resistance to the drug.
Epigenomics will also apply its OncoSign™ approach that is offered in collaboration with its partner CellTrend GmbH (Luckenwalde, Germany) for fast track identification of DNA methylation biomarkers for the drug in an established panel of human tumor cell lines. Financial details were not disclosed.
“We are excited to bring our DMH technology for the discovery of predictive biomarkers to Myriad Genetics, a company well known for its expertise in genetic marker tests,” noted Christina Dahlstroem, Ph.D., Epigenomics’ Senior Vice President Clinical Solutions.
“This collaboration highlights the importance of DNA methylation profiling in the search for biomarkers that will improve therapeutic choices in oncology,” Dahlstroem added.
GlaxoSmithKline plc (GSK) has launched a five-year, $67 million collaboration with the San Francisco and Berkeley campuses of the University of California to build a state-of-the-art laboratory. The goal is to use CRISPR technologies to explore how genes cause disease and to rapidly accelerate the discovery of new drugs.